Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Ilava – page 2

209 clinical trials in Ilava, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Ilava at a glance
209
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

209 trials in Ilava

Open in trial search

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Eltrekibart
  • Sponsor:Eli Lilly & Co.

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Efficacy and safety of weekly subcutaneous zenagamtide versus placebo in adults with type 2 diabetes not controlled by diet and exercise

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Drocamorelin
  • Sponsor:AnaCardio AB

Efficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:NBI-1065890
  • Sponsor:Neurocrine Biosciences Inc.

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Ilava

What the registry says about research in the country

01 Cardiovascular Diseases

The clinical trial activity in Ilava includes research in cardiovascular diseases, with a focus on improving protection against major heart-related events and related complications. These studies are exploring new ways to reduce risk in people living with established or high-risk heart conditions.

  • Atherosclerotic cardiovascular disease
  • Established cardiovascular disease
  • High cardiovascular risk
  • Hypertension

The goal is to evaluate whether new treatments can better prevent serious outcomes such as heart attack, stroke, heart failure, and cardiovascular death.

02 Nutritional and Metabolic Diseases

Another key area in this research landscape is nutritional and metabolic diseases, especially conditions linked to excess weight and metabolic risk. The trials are looking at therapies that may support weight reduction while also improving broader health outcomes.

  • Obesity
  • Overweight
  • Chronic kidney disease

In Ilava, this work is aimed at understanding whether newer treatments can help lower the burden of obesity-related complications and support kidney health at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.